SAN JOSE, Calif., Feb. 25, 2013 /PRNewswire/ -- Ariosa Diagnostics, maker of the non-invasive Harmony™ Prenatal Test for detection of common genetic conditions, has announced the election of Michael A. Aicher to its Board of Directors.
Mr. Aicher has had a very successful career in the molecular diagnostics industry having spent the last 20 years in leadership positions at National Genetics Institute (NGI), a wholly-owned subsidiary of Laboratory Corporation of America® Holdings (LabCorp®), and LabCorp.
As the co-founder and CEO of NGI, Mr. Aicher steered the implementation of an initial treatment model for HCV and secured the first FDA-approved HIV/HCV PCR tests for plasma donor screening, with 15 million donations per year tested. Under various leadership positions at LabCorp, he helped drive revenue and margins within the esoteric testing business. Recognition for Mr. Aicher includes distinction as an Ernst & Young "Entrepreneur of the Year" for Emerging Technologies. Mr. Aicher recently took on the CEO position at Omicia, a DNA sequencing informatics company.
"Ariosa Diagnostics is honored to welcome Michael Aicher to the board. His multiple fields of expertise in strategy and operations within molecular testing will greatly complement the existing board. We are pleased that he will share his leadership and guidance with the team at Ariosa," said Ken Song , MD, CEO of Ariosa.
About Ariosa Diagnostics
Ariosa Diagnostics, Inc. is a molecular diagnostics company committed to innovating together to improve patient care. The flagship product, the Harmony Prenatal Test, is a safe, highly accurate and affordable prenatal test for maternal and fetal heal
|SOURCE Ariosa Diagnostics|
Copyright©2012 PR Newswire.
All rights reserved